Kristin Wynholds - Mar 1, 2023 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role: Chief Product Officer
Signature: /s/ Mark Heinen, Attorney-in-Fact
Stock symbol: BTTX
Transactions as of: Mar 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 4/21/2023, 06:13 PM
Previous filing: Dec 2, 2022
Next filing: Dec 20, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	BTTX	Common Stock	Award	$0	+101K	+102.66%	$0.00	200K	Apr 5, 2023	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	BTTX	Stock Option (Right to Buy)	Award	$0	+101K		$0.00	101K	Mar 1, 2023	Common Stock	101K	$1.14	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The shares represent restricted stock units (each, an "RSU") granted on April 5, 2023, which vest as to 1/2 of the shares on March 24, 2024 and the remaining shares vest on March 24, 2025, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2	The stock option vests as to 1/4 of the shares subject to the stock option on March 1, 2024 and the remaining shares vest in 36 equal monthly installments thereafter, provided the Reporting Person continues to have a service relationship with Issuer on each vesting date. The stock option was granted on March 1, 2023.